Table 3.

Intergroup comparison of key safety endpoints at 1 yr

ATG (n = 113)Daclizumab (n = 114)P value
Bacterial infection, n (%)53 (46.9%)53 (46.5%)NS
No. of bacterial infections/patient (mean ± SD)2.5 ± 1,81.8 ± 1,20.014
Treated cytomegalovirus infection, n (%)21 (18.6%)12 (10.5%)0.093
Sepsis (n, %)8 (7.1%)8 (7.0%)NS
Posttransplant lymphoproliferative disorder00NS
Pneumocystis jiroveci00NS
Fungal infections7 (6.2%)6 (5.3%)NS
Cancer1 (0.9%)0NS
White blood cell count (×103/mm3) (mean ± SD)
    Day 07.2 ± 2.57.1 ± 2.90,7
    1 wk5.3 ± 4.27.8 ± 3.2<0.001
    1 month5.8 ± 2.36.7 ± 2.80.007
    1 yr5.8 ± 2.66.6 ± 2.50.056
Lymphocyte count (×103/mm3) (mean ± SD)
    Day 01.41 ± 0.651.54 ± 0.720.2
    1 wk0.26 ± 0.231.29 ± 0.82<0.001
    1 month0.54 ± 0.401.39 ± 0.97<0.001
    1 yr0.97 ± 0.401.65 ± 0.87<0.001
Neutrophil count (×103/mm3) (mean ± SD)
    Day 04.76 ± 2.294.48 ± 2.100.40
    1 wk4.61 ± 4.235.46 ± 2.420.09
    1 month9.54 ± 4.864.79 ± 2.020.36
    1 yr4.11 ± 2.524.25 ± 1.930.66
Platelet count (×106/mm3) (mean ± SD)
    Day 00.23 ± 0.090.24 ± 0.070.4
    1 wk0.18 ± 0.070.23 ± 0.08<0.001
    1 month0.26 ± 0.100.27 ± 0.100.70
    1 yr0.23 ± 0.070.23 ± 0.070.75